CIK 0001885522 · Non-accelerated filer<br>Smaller reporting company
Neumora Therapeutics, Inc.
Sign in to watch- Ticker
- NMRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844367680
- Phone
- (857) 760-0900
- Business address
- 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $481,506
- in 2 filings
Net −$481,506. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-13 | Fust Matthew K Director | Returned to the company · Stock Option (Right to Buy) | −85,586 | 0 | ||
| 2025-02-13 | Fust Matthew K Director | Returned to the company · Stock Option (Right to Buy) | −27,802 | 0 | ||
| 2025-02-13 | Fust Matthew K Director | Returned to the company · Stock Option (Right to Buy) | −28,571 | 0 | ||
| 2025-02-13 | Fust Matthew K Director | Grant or award · Stock Option (Right to Buy) | +85,586 | 85,586 | ||
| 2025-02-13 | Fust Matthew K Director | Grant or award · Stock Option (Right to Buy) | +27,802 | 27,802 | ||
| 2025-02-13 | Fust Matthew K Director | Grant or award · Stock Option (Right to Buy) | +28,571 | 28,571 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −85,391 | 0 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −38,234 | 0 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −28,675 | 0 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −41,250 | 0 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +85,391 | 85,391 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +38,234 | 38,234 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +28,675 | 28,675 | ||
| 2025-02-13 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +41,250 | 41,250 | ||
| 2025-02-13 | BERNS PAUL L See Remarks | Grant or award · Stock Option (Right to Buy) | +2,000,000 | 2,000,000 | ||
| 2025-02-13 | BERNS PAUL L See Remarks | Returned to the company · Stock Option (Right to Buy) | −497,049 | 0 | ||
| 2025-02-13 | BERNS PAUL L See Remarks | Returned to the company · Stock Option (Right to Buy) | −955,864 | 0 | ||
| 2025-02-13 | BERNS PAUL L See Remarks | Returned to the company · Stock Option (Right to Buy) | −342,500 | 0 | ||
| 2025-02-13 | BERNS PAUL L See Remarks | Grant or award · Stock Option (Right to Buy) | +497,049 | 497,049 |
Page 9 of 20 · 384 trades